Remote Patient Monitoring Startup Funding

What are all the funding deals in the remote patient monitoring market from August 2022 to July 2026?

The table below lists every disclosed equity round raised by pure-play remote patient monitoring companies between August 2022 and July 2026. We count as “pure-play” remote patient monitoring companies those focused on devices, software, analytics, and care workflows that let healthcare providers monitor patients outside traditional clinical settings.

How active has fundraising been in the remote patient monitoring market?

As of July 2026, fundraising in the remote patient monitoring market has been selective rather than dense. Over the past 4 years, companies raised 24 disclosed equity rounds and $536.1M combined, equal to 0.50 deals per month.

The market does not show constant monthly activity. The median number of deals per month is zero, which means many months had no qualifying public funding announcement at all.

Capital flow is also uneven. The market averages $11.17M raised per month, but the median month is still $0 because funding appears in discrete clusters rather than a steady stream.

This is important for interpretation. In the remote patient monitoring market, each credible funding round carries more signal than in categories where new rounds appear every week.

How concentrated has fundraising been in the remote patient monitoring market?

As of July 2026, fundraising in the remote patient monitoring market is moderately concentrated. Over the past 4 years, the largest deal accounts for 18.65% of total capital, the top 3 deals account for 42.53%, and the top 5 deals account for 56.69%.

Cadence’s $100M Series C is the largest deal in the dataset. It materially changes the market total, but it does not dominate the dataset alone.

The top 10 deals account for 77.50% of all disclosed capital. That confirms the remote patient monitoring market has a visible leader group, while smaller specialists still contribute meaningfully to the funding picture.

The right reading is balance. The market is not as concentrated as frontier AI or semiconductor funding, but headline totals still depend heavily on a handful of scale rounds.

How much of the remote patient monitoring funding signal is driven by outliers?

As of July 2026, the remote patient monitoring funding signal is meaningfully shaped by outliers, but not fully explained by them. Over the past 4 years, rounds above $50M represent only 2 deals, or 8.33% of disclosed activity.

Those two large rounds are powerful. Excluding rounds above $50M reduces total capital from $536.1M to $356.1M, removing $180M from the disclosed market total.

That means one-third of the apparent market scale comes from only two deals. This is enough to distort yearly totals, especially when one company raises a large round near the end of the study period.

Still, the baseline market is real. Even without the largest rounds, the remote patient monitoring market shows 22 qualifying financings and more than $350M of disclosed capital.

Is the remote patient monitoring market broad with many targets, or narrow with few fundable companies?

As of July 2026, the remote patient monitoring market is narrow with a limited set of fundable companies. Over the past 4 years, only 21 unique companies produced 24 disclosed qualifying equity rounds.

The low ratio between deals and unique companies means there is not a very large visible pool of venture-backed pure-play RPM companies. The market has a few repeat fundraisers, but not a broad long tail.

HealthSnap, Doccla and RDS each appear twice in the dataset. Their repeat rounds show that follow-on funding tends to follow commercial traction, regulatory progress, or broader health-system deployment.

The exclusion list also matters. Many companies use remote care language, but strict pure-play filtering removes broader virtual-care, home-care, smart-hospital and consumer-wellness businesses from the remote patient monitoring market.

Is remote patient monitoring mostly an early-stage formation market or a late-stage scaling market?

As of July 2026, the remote patient monitoring market is more of a scaling market by dollars, even though Series A is the most common stage by count. Over the past 4 years, early-stage rounds represent 24.86% of capital, while late-stage rounds represent 73.77%.

Series A is the most frequent stage, with 10 of 24 deals. But those Series A deals account for only 20.35% of disclosed capital, which shows many companies are still in validation or early commercialization mode.

Late-stage rounds tell a different story. Series B, Series C, Series D+ and Growth Equity rounds combine for $395.5M, reflecting larger checks for companies with health-system adoption, reimbursement alignment, or workflow proof.

Seed activity is limited. Seed rounds account for 4 deals and $24.15M, so the remote patient monitoring market is not being refreshed by a large wave of newly funded entrants.

Which categories attract the most investor attention in remote patient monitoring?

As of July 2026, Chronic Care Monitoring attracts the most investor attention in the remote patient monitoring market. Over the past 4 years, it accounts for 8 deals and $237.9M, equal to 33.33% of deals and 44.37% of capital.

This category leads because it connects monitoring to recurring care programs. Investors appear to value platforms that can attach device data to chronic disease management, care teams, and measurable utilization outcomes.

Connected Vital Devices ranks second by deal count with 6 deals. However, it represents only 9.62% of capital, which suggests device-led RPM is fundable but harder to scale without workflow or reimbursement depth.

Hospital at Home Platforms also matter. They represent 3 deals and $82.9M, showing that virtual ward capacity remains attractive when it is tied to hospital bed pressure and care delivery redesign.

Which categories attract disproportionately large checks in the remote patient monitoring market?

As of July 2026, Monitoring Data Analytics attracts disproportionately large checks in the remote patient monitoring market. Over the past 4 years, it represents 8.33% of deals but 18.65% of capital, giving it the highest capital share to deal share ratio at 2.24.

The category has only two deals, but the average round size is $50M. Huma and Percipio Health show how investors value device-light layers that turn monitoring data into risk prediction or clinical decision support.

Wearable Health Monitoring also over-indexes on check size, with one $30M deal and a capital share to deal share ratio of 1.34. Chronic Care Monitoring follows closely at 1.33.

Care Coordination Software has the weakest ratio at 0.22. Workflow tools that support monitoring are fundable, but investors do not treat them as large standalone opportunities unless they also own data capture, clinical labor, or reimbursement.

Which geographies matter most for fundraising in the remote patient monitoring market?

As of July 2026, North America matters most for fundraising in the remote patient monitoring market. Over the past 4 years, the region accounts for 15 deals, $337.9M, and 63.03% of total disclosed capital.

Europe is the clear second hub. It produced 8 deals and $192.2M, equal to 35.85% of disclosed capital, with Doccla, Huma and RDS anchoring several of the larger European rounds.

Asia-Pacific appears only once in the dataset, through Dozee’s $6M Series A. That single deal represents 4.17% of deals and 1.12% of disclosed capital.

The geographic pattern is tightly linked to reimbursement and health-system structure. RPM funding concentrates where providers and payers can connect monitoring to care delivery economics.

Is the remote patient monitoring opportunity set broad or concentrated in one hub?

As of July 2026, the remote patient monitoring opportunity set is concentrated in two hubs, not one. Over the past 4 years, North America and Europe together account for 98.88% of disclosed capital.

North America leads on both dollars and deal count. Its 15 deals represent 62.50% of all disclosed activity, which gives it the deepest visible pool of venture-backed RPM companies.

Europe is smaller by count but competitive by check size. Its average deal size is $24.03M, slightly above North America’s $22.53M, mainly because Doccla, Huma and RDS anchor sizable financings.

Latin America, the Middle East and Africa have no qualifying deals in the dataset. This does not imply low healthcare need; it reflects where the investor-backed RPM model has been easiest to finance publicly.

Is remote patient monitoring a market of small experiments or scaled financings?

As of July 2026, the remote patient monitoring market is a mix of mid-sized validation rounds and selective scaled financings. Over the past 4 years, the median round size is $15.3M and the average round size is $22.34M.

The size distribution is concentrated in the middle. There are 4 deals under $5M, 11 deals from $5M to $20M, 7 deals from $20M to $50M, and 2 deals above $50M.

This means the typical RPM deal is not a tiny experiment, but it is also not usually a megaround. Most qualifying companies are raising enough to support clinical deployment, sales expansion, or workflow integration.

The two $50M+ rounds are still important. Cadence and Huma show that investors will write larger checks when remote monitoring is tied to broader chronic care automation or data infrastructure.

Who are the investors that appear the most in remote patient monitoring fundraising?

As of July 2026, repeat investors in the remote patient monitoring market are visible but not widespread. Over the past 4 years, only a small group appears in more than one disclosed qualifying deal.

General Catalyst appears across Doccla’s Series A and Series B financings. That repeat backing reflects conviction in virtual wards and hospital-at-home monitoring as a scalable care model.

Asclepius Growth Capital and Tampa General Hospital / TGH Ventures appear across HealthSnap’s Series A and Series B. This is a useful signal because provider-linked capital can validate commercial relevance in RPM.

Capital Grand Est and MACSF appear across RDS’s Seed and Series A rounds. Their repeat participation shows how regulated connected-device companies often rely on patient, staged capital as they move toward market penetration.

One caveat matters. Round announcements usually disclose participating investors, not exact investor-by-investor check sizes, so repeat appearance is a stronger signal than implied capital committed.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.